Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 11/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 10/20 | 0.39 |
| ▸ | PDE1A | P54750 | 9/20 | 0.39 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021081 | 0.79 | LRRK2 (0.43) | PDE4DPDE1CPDE1BPDE1AALOX15 | |
| SCHEMBL7886968 | 0.78 | ALOX15 (0.44) | PDE4DPDE1CPDE1BPDE1AALOX15 | |
| SCHEMBL15651475 | 0.78 | ALOX15 (0.39) | ALOX15 | |
| SCHEMBL16985266 | 0.77 | TXNRD1 (0.43) | PDE4DPDE1CPDE1BPDE1A | |
| SCHEMBL5021106 | 0.76 | PDE4D (0.43) | PDE4DPDE1CPDE1BPDE1AALOX15 | |
| SCHEMBL16985290 | 0.74 | LRRK2 (0.39) | PDE4DPDE1CPDE1BPDE1AALOX15 | |
| SCHEMBL25753092 | 0.74 | PIK3CD (0.41) | PDE4DPDE1CPDE1BPDE1APDE9A | |
| SCHEMBL30498066 | 0.74 | PIK3CD (0.41) | PDE4DPDE1CPDE1BPDE1APDE9A | |
| SCHEMBL28577114 | 0.72 | PDE4D (0.43) | PDE4DPDE1CPDE1BPDE1ABACE1 | |
| SCHEMBL5021101 | 0.70 | LRRK2 (0.39) | PDE4DPDE1CPDE1BPDE1AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | PDE4D 2789/4885PDE1C 2985/4885PDE1B 2511/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | PDE4D 2463/4885PDE1C 3722/4885PDE1B 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.